CM
ANIP icon

CastleKnight Management’s ANI Pharmaceuticals ANIP Stock Holding History

CastleKnight Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,000
Closed -$415K – 356
2024
Q1 		$415K Sell
6,000
-3,300
-35% -$199K 0.02% 275
2023
Q4 		$513K Buy
+9,300
New +$512K 0.03% 232

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CastleKnight Management's ANIP Position: Q2 2024 in Review

CastleKnight Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2024, closing a stake of 6,000 shares — an estimated $415K sold.

CastleKnight Management first reported a position in ANIP in Q4 2023 and held it in 2 quarters. The position peaked at $513K in Q4 2023. 201 funds tracked by Wall St. Rank hold ANIP as of Q2 2024.

  • CastleKnight Management reported no remaining ANI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • CastleKnight Management sold 6,000 ANI Pharmaceuticals shares in Q2 2024, an estimated $415K.
  • CastleKnight Management first reported a position in ANI Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • CastleKnight Management's ANI Pharmaceuticals position peaked at $513K in Q4 2023.
  • 201 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2024.

Based on CastleKnight Management's 13F filing for Q2 2024, filed 14 Aug 2024.